ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. | SHPH | United States of America | $1.73M | 297 |
| Akari Therapeutics Plc | AKTX | United States of America | $16.13M | 731 |
| Alzamend Neuro, Inc. | ALZN | United States of America | $3.99M | 393 |
| NewcelX Ltd. | NCEL | United States of America | $3.97M | 389 |
| Azitra, Inc. | AZTR | United States of America | $3.42M | 231 |
| Enveric Biosciences, Inc. | ENVB | United States of America | $6.63M | 1,050 |
| Silexion Therapeutics Corp | SLXN | Cayman Islands | $2.75M | 253 |
| Modus Therapeutics Holding AB | MODTX | Sweden | $3.71M | 351 |
| Indaptus Therapeutics, Inc. | INDP | United States of America | $350.43M | 336 |
| Galmed Pharmaceuticals Ltd. | GLMD | Israel | $3.49M | 378 |
| GRI Bio, Inc. | GRI | United States of America | $3.54M | 386 |
| Genprex, Inc. | GNPX | United States of America | $6.95M | 486 |
| Matinas BioPharma Holdings, Inc. | MTNB | United States of America | $4.98M | 579 |
| VALIRX PLC | VAL | United Kingdom | $3.02M | 613 |
| XORTX Therapeutics Inc. | XRTX | Canada | $3.96M | 781 |
| Guard Therapeutics International AB | GUARD | Sweden | $2.81M | 545 |
| GeoVax Labs, Inc. | GOVX | United States of America | $2.69M | 1,227 |
| SciSparc Ltd. | SPRC | United States of America | $6.56M | 2,810 |
| ExpreS2ion Biotech Holding AB | EXPRS2 | Sweden | $1.66M | 1,009 |
| Calidi Biotherapeutics, Inc. | CLDI | United States of America | $2.90M | 406 |
| ORAGENICS INC | OGEN | United States of America | $2.55M | 1,108 |
| Gabather AB | GABA | Sweden | $2.61M | 301 |
| InMed Pharmaceuticals Inc. | INM | Canada | $5.24M | 508 |
| ADIAL PHARMACEUTICALS, INC. | ADIL | United States of America | $2.34M | 566 |
| IO Biotech, Inc. | IOBT | United States of America | $3.45M | 282 |
| AIM ImmunoTech Inc. | AIM | United States of America | $2.32M | 1,547 |
| Biodexa Pharmaceuticals Plc | BDRX | United Kingdom | $2.51M | 760 |
| HCW Biologics Inc. | HCWB | United States of America | $11.67M | 322 |
| PRF Technologies Ltd. | PRFX | United States of America | $1.38M | 252 |
| Ensysce Biosciences, Inc. | ENSC | United States of America | $3.73M | 542 |
| Fluicell AB | FLUI | Sweden | $5.13M | 514 |
| BioSenic SA | BIOS | Belgium | $1.51M | 935 |
| Scinai Immunotherapeutics Ltd. | SCNI | United States of America | $1.77M | 1,880 |
| Biophytis S.A. | ALBPS | France | $2.12M | 594 |
| Propanc Biopharma, Inc. | PPCB | United States of America | $1.68M | 419 |
| BSF ENTERPRISE PLC | BSFA | United Kingdom | $1.50M | 191 |
| Clearmind Medicine Inc. | CMND | Canada | $3.51M | 352 |
| Carisma Therapeutics Inc. | CARM | United States of America | $255k | 862 |
| Abpro Holdings, Inc. | ABP | United States of America | $1.42M | 251 |
| CNS Pharmaceuticals, Inc. | CNSP | United States of America | $7.31M | 395 |
| Stayble Therapeutics AB | STABL | Sweden | $1.41M | 167 |
| Lyra Therapeutics, Inc. | LYRA | United States of America | $1.26M | 375 |
| Protagenic Therapeutics, Inc.\new | PTIX | United States of America | $1.10M | 698 |
| CERO THERAPEUTICS HOLDINGS, INC. | CERO | United States of America | $474k | 444 |
| PCI Biotech Holding | PCIB | Norway | $538k | 983 |
| Medigene AG | MDG1 | Germany | $484k | 331 |
| Aditxt, Inc. | ADTX | United States of America | $51k | 595 |
| Lipigon Pharmaceuticals AB | LPGO | Sweden | $350k | 315 |
| Coiled Therapeutics PLC | ROQ | United Kingdom | $208k | 204 |
| QUIA PHARMA AB | QUIA | Sweden | $140k | 546 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.